[go: up one dir, main page]

WO2005097980A3 - New protocols for making hepatocytes from embryonic stem cells - Google Patents

New protocols for making hepatocytes from embryonic stem cells Download PDF

Info

Publication number
WO2005097980A3
WO2005097980A3 PCT/US2005/009972 US2005009972W WO2005097980A3 WO 2005097980 A3 WO2005097980 A3 WO 2005097980A3 US 2005009972 W US2005009972 W US 2005009972W WO 2005097980 A3 WO2005097980 A3 WO 2005097980A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
stem cells
hepatocytes
making
embryonic stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/009972
Other languages
French (fr)
Other versions
WO2005097980A2 (en
Inventor
Ramkumar Mandalam
Saadia Faouzi
Isabelle Nadeau-Demers
Kristina Bonham
Namitha Rao
Melissa K Carpentier
Lakshmi Rambhatla
Choy-Pik Chiu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geron Corp
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of WO2005097980A2 publication Critical patent/WO2005097980A2/en
Anticipated expiration legal-status Critical
Publication of WO2005097980A3 publication Critical patent/WO2005097980A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C12N5/0672—Stem cells; Progenitor cells; Precursor cells; Oval cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/065—Modulators of histone acetylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/12—Hepatocyte growth factor [HGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/148—Transforming growth factor alpha [TGF-a]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

This disclosure provides a newly developed strategy and particular options for differentiating pluripotent stem cells into cells of the hepatocyte lineage. Many of the protocols are based on a strategy in which the cells are first differentiated into early germ layer cells, then into hepatocyte precursors, and then into mature cells. The cells obtained have morphological features and phenotypic markers characteristic of human adult hepatocytes. They also show evidence of cytochrome p450 enzyme activity, validating their utility for commercial applications such as drug screening, or use in the manufacture of medicaments and medical devices for clinical therapy.
PCT/US2005/009972 2004-03-26 2005-03-24 New protocols for making hepatocytes from embryonic stem cells Ceased WO2005097980A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55683004P 2004-03-26 2004-03-26
US60/556,830 2004-03-26

Publications (2)

Publication Number Publication Date
WO2005097980A2 WO2005097980A2 (en) 2005-10-20
WO2005097980A3 true WO2005097980A3 (en) 2007-12-27

Family

ID=35125673

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/009972 Ceased WO2005097980A2 (en) 2004-03-26 2005-03-24 New protocols for making hepatocytes from embryonic stem cells

Country Status (1)

Country Link
WO (1) WO2005097980A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815591B2 (en) 2005-06-24 2014-08-26 Icahn School Of Medicine At Mount Sinai Mesoderm and definitive endoderm cell populations
US9132226B2 (en) 2008-11-14 2015-09-15 Viacyte, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
US9980986B2 (en) 2006-03-02 2018-05-29 Viacyte, Inc. Methods of producing pancreatic hormones
US10295543B2 (en) 2006-06-23 2019-05-21 Rutgers, The State University Of New Jersey Method of overcoming therapeutic limitations of non-uniform distribution of radiopharmaceuticals and chemotherapy drugs

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2361966A1 (en) 2002-05-17 2011-08-31 Mount Sinai School of Medicine of New York University Mesoderm and definitive endoderm cell populations
JP4819697B2 (en) 2003-12-23 2011-11-24 ヴィアサイト，インコーポレイテッド Definitive endoderm
US7625753B2 (en) 2003-12-23 2009-12-01 Cythera, Inc. Expansion of definitive endoderm cells
US7985585B2 (en) 2004-07-09 2011-07-26 Viacyte, Inc. Preprimitive streak and mesendoderm cells
US8586357B2 (en) 2003-12-23 2013-11-19 Viacyte, Inc. Markers of definitive endoderm
US20050266554A1 (en) 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
US8647873B2 (en) 2004-04-27 2014-02-11 Viacyte, Inc. PDX1 expressing endoderm
MX2007001772A (en) 2004-08-13 2007-07-11 Univ Georgia Res Found Compositions and methods for self-renewal and differentiation in human embryonic stem cells.
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
EP2674485B1 (en) 2005-10-27 2019-06-12 Viacyte, Inc. Pdx-1 expressing dorsal and ventral foregut endoderm
US8129182B2 (en) 2006-03-02 2012-03-06 Viacyte, Inc. Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
US11254916B2 (en) 2006-03-02 2022-02-22 Viacyte, Inc. Methods of making and using PDX1-positive pancreatic endoderm cells
WO2007127454A2 (en) 2006-04-28 2007-11-08 Cythera, Inc. Hepatocyte lineage cells
AU2007256393A1 (en) 2006-06-04 2007-12-13 Cellartis Ab Novel hepatocyte-like cells and hepatoblast-like cells derived from hBS cells
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
EP2185693B1 (en) 2007-07-31 2019-07-03 Lifescan, Inc. Differentiation of human embryonic stem cells
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
ATE523585T1 (en) 2007-11-27 2011-09-15 Lifescan Inc DIFFERENTIATION OF HUMAN EMBRYONAL STEM CELLS
CN105886459A (en) 2008-02-21 2016-08-24 詹森生物科技公司 Methods, surface modified plates and compositions for cell attachment, cultivation and detachment
BRPI0914116A2 (en) 2008-06-30 2019-09-17 Centocor Ortho Biotech Inc pluripotent stem cell differentiation
CN107904201B (en) 2008-10-31 2021-11-16 詹森生物科技公司 Differentiation of human embryonic stem cells into the pancreatic endocrine lineage
KR101798474B1 (en) 2008-10-31 2017-11-16 얀센 바이오테크 인코포레이티드 Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
PL2366022T3 (en) 2008-11-20 2016-11-30 Methods and compositions for cell attachment and cultivation on planar substrates
CN102307991B (en) 2008-11-20 2017-08-15 森托科尔奥索生物科技公司 Pluripotent Stem Cell Culture on Microcarriers
WO2010151782A1 (en) 2009-06-25 2010-12-29 Geron Corporation Differentiated pluripotent stem cell progeny depleted of extraneous phenotypes
AU2010276438B2 (en) 2009-07-20 2015-06-11 Janssen Biotech Inc. Differentiation of human embryonic stem cells
KR101773538B1 (en) 2009-12-23 2017-08-31 얀센 바이오테크 인코포레이티드 Differentiation of human embryonic stem cells
CN102791851B (en) 2010-03-01 2017-07-14 詹森生物科技公司 Method of purifying cells derived from pluripotent stem cells
KR101903562B1 (en) 2010-05-12 2018-10-02 얀센 바이오테크 인코포레이티드 Differentiation of human embryonic stem cells
MX355340B (en) 2010-08-31 2018-04-16 Janssen Biotech Inc DIFFERENTIATION OF HUMAN EMBRYOUS MOTHER CELLS.
MX355077B (en) 2010-08-31 2018-04-03 Janssen Biotech Inc Differentiation of human embryonic stem cells.
MX348537B (en) 2010-08-31 2017-06-07 Janssen Biotech Inc Differentiation of pluripotent stem cells.
WO2012135253A1 (en) 2011-03-29 2012-10-04 Geron Corporation Enriched populations of cardiomyocyte lineage cells from pluripotent stem cells
RU2668798C2 (en) 2011-12-22 2018-10-02 Янссен Байотек, Инк. Methods for in vitro of step-by-step differentiation of pluripotent cells
SG11201405052RA (en) 2012-03-07 2014-10-30 Janssen Biotech Inc Defined media for expansion and maintenance of pluripotent stem cells
EP3450542B1 (en) 2012-06-08 2021-09-01 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
MX2015008578A (en) 2012-12-31 2015-09-07 Janssen Biotech Inc Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators.
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
AU2013368221B2 (en) 2012-12-31 2018-11-01 Janssen Biotech, Inc. Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
AU2013370228B2 (en) 2012-12-31 2018-10-18 Janssen Biotech, Inc. Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells
MX2016015004A (en) 2014-05-16 2017-06-27 Janssen Biotech Inc Use of small molecules to enhance mafa expression in pancreatic endocrine cells.
GB201521179D0 (en) 2015-12-01 2016-01-13 Univ Leuven Kath Methods for differentiating cells into hepatic stellate cells
MA45479A (en) 2016-04-14 2019-02-20 Janssen Biotech Inc DIFFERENTIATION OF PLURIPOTENT STEM CELLS IN ENDODERMAL CELLS OF MIDDLE INTESTINE
CN109022352A (en) * 2018-08-27 2018-12-18 芜湖职业技术学院 The method for improving extracorporeal embryo development
CN115551994A (en) 2020-03-11 2022-12-30 倍特博有限公司 Method for producing hepatocytes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458589B1 (en) * 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458589B1 (en) * 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
US6506574B1 (en) * 2000-04-27 2003-01-14 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZARET K.: "Hepatocyte differentiation: from the endoderm and beyond", CURRENT OPINION IN GENETICS & DEVELOPMENT, vol. 11, 2001, pages 568 - 574, XP002959536, DOI: doi:10.1016/S0959-437X(00)00234-3 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815591B2 (en) 2005-06-24 2014-08-26 Icahn School Of Medicine At Mount Sinai Mesoderm and definitive endoderm cell populations
US9980986B2 (en) 2006-03-02 2018-05-29 Viacyte, Inc. Methods of producing pancreatic hormones
US10295543B2 (en) 2006-06-23 2019-05-21 Rutgers, The State University Of New Jersey Method of overcoming therapeutic limitations of non-uniform distribution of radiopharmaceuticals and chemotherapy drugs
US9132226B2 (en) 2008-11-14 2015-09-15 Viacyte, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells

Also Published As

Publication number Publication date
WO2005097980A2 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
WO2005097980A3 (en) New protocols for making hepatocytes from embryonic stem cells
WO2007115336A3 (en) A shape-based approach for scaffoldless tissue engineering
WO2006050330A3 (en) Platelets from stem cells
WO2007028065A3 (en) Chimeric oligomeric compounds for modulation of splicing
ATE468111T1 (en) COMPOSITION IN MICROPELLETS WITH CONTROLLED RELEASE OF PHYSIOLOGICAL ACTIVE SUBSTANCES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN THE ZOOTECHNICAL SECTOR
WO2008013773A3 (en) Quinine products, method of manufacture, and method of use
ATE486126T1 (en) LIVER PRECURSOR CELLS
ZA200900788B (en) Manufacture,method,and use of active substance-releasing medical products for permanently keeping blood vessels open
WO2008067389A3 (en) Modulation of sod protein synthesis for the treatment of neurodegenerative diseases
WO2007119213A3 (en) A culture medium and pharmaceutical composition for regenerating cartilage tissue, a method, uses and products related thereto
WO2008052770A3 (en) (base-)modified rna for increasing the expression of a protein
WO2007030811A3 (en) Tissue engineering methods and compositions
EP1302536A3 (en) Embryonic stem cells and neural progenitor cells derived therefrom
IL186228A0 (en) Preparation of autologous haematopoietic stem cells, the methods of production, cryopreservation and use for therapy of traumatic diseases of the central nervous system
WO2005113752A3 (en) Methods and compositions for producing germ cells from peripheral blood derived germline stem cells
IL197575A (en) Method for the expansion of adult stem cells from blood, use thereof for the preparation of medicament for the treatment of lesions and pharmaceutical composition comprising said adult stem cells
WO2004072265A3 (en) Methods for monitoring drug activities in vivo
WO2007136760A3 (en) Method of growth of mesenchymal cells under non-adherent conditions for clinical applications
SI1750700T1 (en) Liquid preparation for veterinary medicine, method for the production thereof, and use of the same
WO2008026226A3 (en) Self-renewing master adult pluripotent stem cells
WO2006055841A3 (en) Indefinite culture of human adult glia without immortalization and therapeutic uses thereof
WO2007135563A3 (en) Use of glis3 for preparing functional pancreatic beta-cells
IL178094A (en) Enantiomeric compounds, use thereof for the treatment or prevention of viral diseases, autoimmune diseases or organ or tissue transplantation rejection and methods of making same
WO2007137301A3 (en) Modulation of chrebp expression
IL177671A0 (en) Pluripotent embryonic-like stem cells derived from corneal limbus, methods of isolation and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase